AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 FEB 15 - (NewsRx.com) -- Sonia Nichols, staff medical writer -- Important information about the ratio of two enzymes found in epithelial ovarian cancer tissues could potentially be used to develop new anti-cancer therapies.
Although neither of the enzymes alone is an independent predictor of patient outcome, when jointly examined in terms of their ratios, they are significant indicators for survival, researchers at Shimane Medical University report.
Dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP) are the two enzymes described in the Journal of Clinical Oncology by R. Fujiwaki et al. Both have a significant relationship to thymine. According to investigators, (DPD) degrades thymine, while TP is the catalyst that changes thymidine into thymine.
For this study, 85 epithelial ovarian cancers were compared with 27 normal ovaries. In each sample, Fujiwaki and associates examined DPD and TP gene expression using standard laboratory methodologies.
"DPD gene expression was significantly lower in epithelial ovarian cancers than in normal ovaries (P[less than]0.0001), whereas TP gene expression and the ratio of TP to DPD gene expression (TP:DPD) were significantly higher in epithelial ovarian cancer (P[less than]0.0001 for both)," noted Fujiwaki et al.
Neither DPD nor the ratio tended to correlate with any one particular finding relative to clinical appearance, according to ...
Source: HighBeam Research, Enzymatic Compounds are Prognostic for Survival.(of ovarian cancer)